Discovery and development of therapeutic aptamers

Annual Review of Pharmacology and Toxicology

Volumn 50, Issue , 2010, Pages 237-257

  Bouchard, P R ^a,b   Hutabarat, R M ^a,c   Thompson, K M ^a  

^a Archemix Corporation   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

Metabolism; PEG; Pharmacokinetics; SELEX; Toxicology

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APTAMER; ARC 1779; ARC 1905; AS 1411; CYTOCHROME P450; E 10030; NU 172; PEGAPTANIB; REG 1; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANION EXCHANGE CHROMATOGRAPHY; BINDING AFFINITY; BIOTECHNOLOGY; CLINICAL TRIAL; COMBINATORIAL CHEMISTRY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG STABILITY; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CARCINOMA; LIQUID CHROMATOGRAPHY; MOLECULAR STABILITY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; REVIEW; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; THROMBOTIC THROMBOCYTOPENIC PURPURA; TOXICITY TESTING; WHOLE BODY AUTORADIOGRAPHY; ANIMAL; METABOLISM;

ANIMALS; APTAMERS, NUCLEOTIDE; HUMANS; SELEX APTAMER TECHNIQUE;

EID: 77649103704     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.010909.105547     Document Type: Review

References (64)

1. Brody EN, Gold L. 2000. Aptamers as therapeutic and diagnostic agents. Rev. Mol. Biotechnol. 74:2-13
2. Proske D, Blank M, Buhmann R, Resch A. 2005. Aptamers: basic research, drug development, and clinical applications. Appl. Microbiol. Biotechnol. 69:367-374
3. Pestourie C, Tavitian B, Duconge F. 2005. Aptamers against extracellular targets for in vivo applications. Biochemie 87:921-930
4. Nimjee SM, Rusconi CP, Harrington RA, Sullenger BA. 2005. The potentialofaptamersasanticoagulants. Trends Cardiovasc. Med. 15:41-45
5. Lee JF, Stovall GM, Ellington AD. 2006. Aptamer therapeutics advance. Curr. Opin. Chem. Biol. 10:282-289
6. Osborne SE, MatsumuraI, Ellington AD. 1997. Aptamersastherapeutic and diagnostic reagents: problems and prospects. Curr. Opin. Chem. Biol. 1:5-9
7. Keefe AD, Cload ST. 2008. SELEX with modified nucleotides. Curr. Opin. Chem. Biol. 12:448-456
8. Marshall KA, Ellington AD. 2000. In vitro selection of RNA aptamers. Methods Enzymol. 318:193-214
9. Kaur G, Roy I. 2008. Therapeutic applications of aptamers. Expert Opin. Investig. Drugs 17:43-60
10. Wilson C. 2008. Aptamer opportunities and challenges. In Antisense Drug Technology, Principles, Strategies and Applications, ed. S Crooke, pp. 773-799 Boca Raton, FL: Taylor & Francis
11. Tuerk C, Gold L. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510
12. Ellington AD, Szostak JW. 1990. In vitro selection of RNA molecules that bind specific ligands. Nature 346:818-822
13. Sousa R, Padilla R. 1995. A mutant T7 RNA polymerase as a DNA polymerase. EMBOJ. 14:4609-4621
14. Vater A, Klussmann S. 2003. Toward third-generation aptamers: Spiegelmers and their therapeutic prospects. Curr. Opin. Drug Discov. Dev. 6:253-261
15. Clauss S, Gross O, Kulkarni O, Avila-Ferrufino A, Radomska E, et al. 2009. Ccl2/Mcp-1 blockade reduces glomerular and interstitial macrophages but does not ameliorate renal pathology in collagen4A3-deficient mice with autosomal recessive Alport nephropathy. J. Pathol. 218:40-47
16. Edvinsson L, Nilsson E, Jansen-Olesen I. 2007. Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br. J. Pharmacol. 150:633-640
17. Shearman LP, Wang SP, Helmling S, Stribling DS, Mazur P, et al. 2006. Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 147:1517-1526
18. Helmling S, Maasch C, Eulberg D, Buchner K, Schroder W, et al. 2004. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. Proc. Natl. Acad. Sci. USA 101:13174-13179
19. Leva S, Lichte A, Burmeister J, Muhn P, Jahnke B, et al. 2002. GnRH binding RNA and DNA Spiegelmers: a novel approach toward GnRH antagonism. Chem. Biol. 9:351-359
20. Bailon P, Won CY. 2009. PEG-modified biopharmaceuticals. Expert Opin. Drug Deliv. 6:1-16
21. Jain A, Jain SK. 2008. PEGylation: an approach for drug delivery. A review. Crit. Rev. Ther. Drug Carrier Syst. 25:403-447
22. Veronese FM, Mero A. 2008. The impact of PEGylation on biological therapies. BioDrugs 22:315-329
23. Veronese FM, Pasut G. 2005. PEGylation, successful approach to drug delivery. Drug Discov. Today 10:1451-1458
24. Hamidi M, Azadi A, Rafiei P. 2006. Pharmacokinetic consequences of pegylation. DrugDeliv. 13:399-409
25. Diener J, Lagasse D, Duerschmied D, Merhi Y, Tanguay JF, et al. 2009. Inhibition of von Willebrand Factor-mediated platelet activation and thrombosis by anti-von Willebrand Factor A1-domain aptamer ARC1779.J. Thromb. Haemost. 7:1155-1162
26. Levin AA, Yu RZ, Geary RS. 2008. Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. See Ref. 10, pp. 183-215
27. Wu H, MacLeod AR, Lima WF, Crooke ST. 1998. Identification and partial purification of human double strand RNase activity. A novel terminating mechanism for oligoribonucleotide antisense drugs. J. Biol. Chem. 273(5):2532-2542
28. HutabaratRM, Chung J, Lewis SL, Cai L, McCauley TG, Bouchard P. 2008. Metabolic stability, metabolite identification and nuclease cleavages identification by LC/MS/MS during aptamer lead series optimization. Presented at National Biotechnology Conference
29. Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, et al. 2000. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res. 17:1503-1510
30. McCauley TG, Kurz JC, Merlino PG, Lewis SD, Gilbert M, et al. 2006. Pharmacologic and pharmacokinetic assessment of anti-TGFbeta2 aptamers in rabbit plasma and aqueous humor. Pharm. Res. 23:303-311
31. Leeds JM, Henry SP, Geary R, Burckin T, Levin AA. 2000. Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys. Antisense Nucleic Acid Drug Dev. 10:435-441
32. Farman CA, Kornbrust DJ. 2003. Oligodeoxynucleotide studies in primates: antisense and immune stimulatory indications. Toxicol. Pathol. 31(Suppl):119-122
33. Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, et al. 2003. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab. Dispos. 31(11):1419-1428
34. U.S Food and Drug Administration. 2004. Macugen, Pegaptanib Sodium. FDA Pharmacology Review. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
35. Boomer RM, Lewis SD, Healy JM, Kurz M, Wilson C, McCauley TG. 2005. Conjugation to polyethylene glycol polymer promotes aptamer distribution to healthy and inflamed tissues. Oligonucleotides 15:183-195
36. Phillips JA, Craig SJ, Bayley D, Christian RA, Geary R, Nicklin PL. 1997. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol. 54(6):657-668
37. Graham MJ, Crooke ST, Monteith DK, Cooper SR, Lemonidis KM, et al. 1998. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J. Pharmacol. Exp. Ther. 286(1):447-458
38. Geary RS, Khatsenko O, Bunker K, Crooke R, Moore M, et al. 2001. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J. Pharmacol. Exp. Ther. 296(3):898-904
39. DeAnda A Jr, Coutre SE, Moon MR, Vial CM, Griffin LC, et al. 1994. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann. Thorac. Surg. 58:344-350
40. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, et al. 2007. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116:2678-2686
41. Henry SP, Kim TW, Kramer-Strickland K, Zanardi TA, Fey RA, Levin AA. 2008. Toxicological properties of 2'-O-methoxyethyl chimeric antisense inhibitors in animals and man. See Ref 10, pp. 327-363
42. Marquis JK, Grindel JM. 2000. Toxicological evaluation of oligonucleotide therapeutics. Curr. Opin. Mol. Ther. 2:258-263
43. Henry SP, Giclas PC, Leeds J, PangburnM, Auletta C, et al. 1997. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J. Pharmacol. Exp. Ther. 281:810-816
44. Henry SP, Beattie G, Yeh G, Chappel A, Giclas P, et al. 2002. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int. Im-munopharmacol. 2:1657-1666
45. Sheehan JP, Lan HC. 1998. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 92:1617-1625
46. Vollmer J, Krieg AM. 2008. Mechanisms and therapeutic applications of immune modulatory oligodeoxynucleotide and oligoribonucleotide ligands for toll-like receptors. See Ref. 10, pp. 747-772
47. Barchet W, Wimmenauer V, Schlee M, Hartmann G 2008. Accessing the therapeutic potential of im-munostimulatory nucleic acids. Curr. Opin. Immunol. 20:389-395
48. Goebl N, Berridge B, Wroblewski VJ, Brown-Augsburger PL. 2007. Development of a sensitive and specific in situ hybridization technique for the cellular localization of antisense oligodeoxynucleotide drugs in tissue sections. Toxicol. Pathol. 35:541-548
49. Bendele A, Seely J, Richey C, Sennello G, Shopp G 1998. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol. Sci. 42:152-157
50. U.S Food and Drug Administration. 2008. Cimzia, Certolizumab pegol. FDA Pharmacology Review.
51. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
52. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. 2006. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5:123-132
53. Ciulla TA, Rosenfeld PJ. 2009. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr. Opin. Ophthalmol. 20:158-165
54. Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, et al. 2006. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114:2490-2497
55. Chan MY, Rusconi CP, Alexander JH, Tonkens RM, Harrington RA, Becker RC. 2008. A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J. Thromb. Haemost. 6:789-796
56. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, et al. 2008. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 117:2865-2874
57. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. 2009. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol. 86:151-164
58. Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. 2008. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 68:2358-2365
59. Ireson CR, Kelland LR. 2006. Discovery and development of anticancer aptamers. Mol. Cancer Ther. 5:2957-2962
60. Jo N, Mailhos C, Ju M, Cheung E, Bradley J, et al. 2006. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am. J. Pathol. 168:2036-2053
61. Sennino B, Falcón BL, McCauley D, Le T, McCauley T, et al. 2007. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res. 67:7358-7367
62. Biesecker G, Dihel L, Enney K, Bendele RA. 1999. Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology 42:219-230
63. Kurz JC, Rottman JB, McCauley TM, Benedict C, Epstein D. 2005. In vitro and in vivo studies of a synthetic anti-C5 aptamer. Presented at 3rd Workshop on Complement Associated Diseases, Animal Models, and Therapeutics
64. Wagner-Whyte J, Khuri S, Olsen K, Hatala P, Boomer RM, et al. 2007. Discovery of an extremely potent aptamer direct thrombin inhibitor. ISTH Conference